The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Verbovoĭ A.F.

Kafedra éndokrinologii Samarskogo gosudarstvennogo meditsinskogo universiteta

Tsanava I.A.

Samara State Medical University, Health Ministry of Russia, Samara, Russia

Mitroshina E.V.

Samara State Medical University, Samara, Russia

Sharonova L.A.

Samara State Medical University, Health Ministry of Russia, Samara, Russia

Osteoprotegerin is a new marker of cardiovascular diseases

Authors:

Verbovoĭ A.F., Tsanava I.A., Mitroshina E.V., Sharonova L.A.

More about the authors

Journal: Therapeutic Archive. 2017;89(4): 91‑94

DOI: 10.17116/terarkh201789491-94

Read: 3044 times

Download PDF (RU)
Contact the author
Table of contents

OSTEOPROTEGERIN IS A NEW MARKER OF CARDIOVASCULAR DISEASES
OSTEOPROTEGERIN IS A NEW MARKER OF CARDIOVASCULAR DISEASES

To cite this article:

Verbovoĭ AF, Tsanava IA, Mitroshina EV, Sharonova LA. Osteoprotegerin is a new marker of cardiovascular diseases. Therapeutic Archive. 2017;89(4):91‑94. (In Russ.)
https://doi.org/10.17116/terarkh201789491-94

МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
The significance of exogenous nitrate and nitrite of plant origin for vascular health. Russian Journal of Preventive Medi­cine. 2024;(11):141-146
The improvement of the specialized medi­cal care for patients with peri­pheral arte­rial athe­rosclerosis in the Yaro­slavl region. Russian Journal of Preventive Medi­cine. 2024;(12):16-23
Long-term outcomes in patients after hospital treatment for COVID-19 (three-year follow-up data). Russian Journal of Preventive Medi­cine. 2024;(12):114-121
Asso­ciation of the subclinical athe­rosclerosis with addi­tional risk factors for chro­nic non-communicable diseases. Russian Journal of Preventive Medi­cine. 2024;(12):151-155
Personalized approach to treatment choice using a digi­tal profile of patient with cardiovascular diseases: the features of clinical deci­sion-making support service. Russian Cardiology Bulletin. 2024;(4-2):105-112
A pilot study of the rela­tionship between cardiovascular risk and routine mammography data in women. Russian Cardiology Bulletin. 2024;(4-2):154-160
Giant popliteal artery aneurysm. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(1):115-119
Psoriasis: analysis of como­rbid pathology. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(1):16-21
Risk factors and adve­rse outcomes of cardiovascular diseases in people with high normal blood pressure of the Ryazan region. (5-year prospective follow-up). Russian Journal of Preventive Medi­cine. 2025;(2):31-37
Increased expression of circular RNA circSPARC and circTMEM181 in coro­nary athe­rosclerosis. Mole­cular Gene­tics, Microbiology and Viro­logy. 2025;(1):24-29
Abstract:

Osteoprotegerin (OPG) is a glycoprotein that is a representative of the tumor necrosis factor-α receptor superfamily. Information about the possible role of OPG in the development of cardiovascular diseases has begun to appear in the literature in recent years. This review discusses the role of increasing the level of OPG in the development and progression of atherosclerosis and as a consequence of coronary heart disease and chronic heart failure.

Keywords:

osteoprotegerin
cardiovascular diseases
atherosclerosis

Authors:

Verbovoĭ A.F.

Kafedra éndokrinologii Samarskogo gosudarstvennogo meditsinskogo universiteta

Tsanava I.A.

Samara State Medical University, Health Ministry of Russia, Samara, Russia

Mitroshina E.V.

Samara State Medical University, Samara, Russia

Sharonova L.A.

Samara State Medical University, Health Ministry of Russia, Samara, Russia

Close metadata

References:

  1. http://www.who.int/mediacentre/factsheets/fs317/ru/
  2. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89(2):309-319. doi:10.1016/s0092-8674(00)80209-3
  3. Ueland T, Odgren PR, Yndestad A, Godang K, Schreiner T, Marks SC, Bollerslev J. Growth hormone substitution increases gene expression of members of the IGF family in cortical bone from women with adult onset growth hormone deficiency — relationship with bone turn-over. Bone. 2003;33(4):638-645. doi:10.1016/s8756-3282(03)00240-0
  4. Olesen P, Ledet T, Rasmussen LM. Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-alpha. Diabetologia. 2005;48(3):561-568. doi:10.1007/s00125-004-1652-8
  5. Browner WS, Lui LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, strokes, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab. 2001;86(2):631-637. doi:10.1210/jc.86.2.631
  6. Colledge J, McCann M, Mangan S et al. Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. Stroke. 2004;35:1636-1641. doi:10.1161/01.str.0000129790.00318.a3
  7. Crisafulli A, Romeo A, Floccari F, Aloisi E et al. Osteoprotegerin and bone mineral density in hemodiafiltration patients. Ren Fail. 2005;27(5):531-539. doi:10.1080/08860220500198698
  8. Ueland T, Yndestad A, Qie E, Florholmen G et al. Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. Circulation. 2005;111(19):2461-2468. doi:10.1161/01.cir.0000165119.62099.14
  9. Ziegler S, Kudlacek S, Luger A, Minar E. Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease. Atherosclerosis. 2005;182(1):175-180. doi:10.1016/j.atherosclerosis.2005.01.042
  10. Kadoglou NP, Gerasimidis T, Golemati S, Kapelouzou A et al. The relationship between serum levels of vascular calcification inhibitors and carotid plaque vulnerability. J Vasc Surg. 2008;47(1):55-62. doi:10.1016/s0749-4041(09)79190-0
  11. Sandberg WJ, Yndestad A, Qie E, Smith C et al. Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization. Arterioscler Thromb Vasc Biol. 2006;26(4):857-863. doi:10.1161/01.atv.0000204334.48195.6a
  12. Song TJ, Kim J, Yang SH, Park JH et al. Association of plasma osteoprotegerin levels with stroke severity and functional outcome in acute ischaemic stroke patients. Biomarkers. 2012;17(8):738-744. doi:10.3109/1354750x.2012.727027
  13. Knudsen ST, Foss CH, Poulsen PL, Mogensen CE, Rasmussen LM. Increased plasma concentrations of osteoprotegerin in diabetic patients with microvascular complications. European Journal of Endocrinology. 2003;149:39-42. doi:10.1530/eje.0.1490039
  14. Xiang GD, Xu L, Zhao LS et al. The relationship between plasma osteoprotegerin and endothelium-dependent arterial dilation in type 2 diabetes. Diabetes. 2006;55(7):2126-2131. doi:10.2337/db06-0231
  15. Verbovoj A, Akimova D, Verbovaja N. Status of bone mineral density and bone metabolism parameters in women with type 2 diabetes. Jendokrinologija: novosti, mnenija, obuchenie. 2014;1(5):39-43. (In Russ.)
  16. Verbovoj A, Sharonova L, Kapishnikov A, Demidova D. Vitamin D3, osteoprotegerin and other hormonal and metabolic parameters in women with type 2 diabetes. Ozhirenie i etabolism. 2012;4(33):23-27. (In Russ.)
  17. Verbovoj A, Sharonova L, Kapishnikov A, Demidova D. Vitamin D3, osteoprotegerin and other hormonal and metabolic parameters in men with type 2 diabetes. Terapevt. 2013;1:42-48. (In Russ.)
  18. Verbovoj A, Sharonova L, Verbovaja N et al. The content of vitamin D3 and indices of bone metabolism in women with type 2 diabetes. Farmateka. 2013;5(258):48-51. (In Russ.)
  19. Verbovoj A, Sharonova L, Verbovaja N, Akimova D. The content of vitamin D3 and indices of bone metabolism in men with type 2 diabetes. Osteoporoz I osteopatii. 2014;1:8-10. (In Russ.)
  20. Boyadzhieva M, Hristozov K, Georgiev S, Yordanov R et al. High osteoprotegerin serum levels in newly diagnosed type 2 diabetic males with or without known coronary artery disease. Diabetologia. 2010;53(Suppl.1):S491. doi:10.14748/ssm.v45i3.308
  21. Barabanova N, Verbovoj A, Lebedev P. The role of osteoprotegerin in the development of atherosclerosis in patients with type 2 diabetes. Теrapevt. 2014;1:4-10. (In Russ.)
  22. Jaroslavceva M, Ul’janova I, Galstjan G, Il’in A et al. Osteoprotegerin system (opg) receptor-ligand activator of nuclear factor kappa B (RANKL) in patients with diabetes, mediakaltsinozom and atherosclerosis obliterans of lower limb arteries. Saharnyj diabet. 2009;1:25-28. (In Russ.)
  23. Verbovaja N, Kapralova I, Verbovoj A. The content of osteoprotegerin and adipokines in hypothyroidism in women. Vrach. 2014;8:66-68. (In Russ.)
  24. Kiechl S, Schett G, Wenning G, Redlich K, Oberhollenzer M, Mayr A, Santer P, Smolen J, Poewe W, Willeit J. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation. 2004;109(18):2175-2180. doi:10.1161/01.cir.0000127957.43874.bb
  25. Soro-Paavonen A, Gordin D, Forsblom C, Rosengard-Barlund M. Osteoprotegerin is increased in patients with type 1 diabetes and vascular complications and predicts cardiovascular mortality. Diabetologia. 2011;54(Suppl.1):S57.
  26. Omland T, Drazner MH, Ueland T et al. Plasma osteoprotegerin levels in the general population: relation to indices of left ventricular structure and function. Hypertension. 2007;49:1392-1398. doi:10.1161/hypertensionaha.107.087742
  27. Jono S, Ikari Y, Shioni A. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation. 2002;106:1192-1194. doi:10.1161/01.cir.0000031524.49139.29
  28. Schoppet M, Sattler AM, Schaefer JR, Herzum M et al. Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab. 2003;88(3):1024-1028. doi:10.1210/jc.2002-020775
  29. Ueland T, Dahl CP, Kjekshus J, Hulthe J et al. Osteoprotegerin predicts progression of chronic heart failure: results from CORONA. Circ Heart Fail. 2011;4(2):145-52. doi:10.1161/circheartfailure.110.957332
  30. Kjekshus J, Apetrei E, Barrios V, Bohm M. Rosuvastatin in older patients with systolic heart failure. N Eng J Med. 2007;357(22):2248-2261.
  31. Nellemann B, Gormsen LC, Dollerup J, Schmitz O et al. Simvastatin reduces plasma osteoprotegerin in type 2 diabetic patients with microalbuminuria. Diabetes Care. 2007;30(12):3122-3124. doi:10.2337/dc07-0919
  32. Andersen GО, Knudsen EC, Aukrust P, Yndestad A, Oie E, Müller C, Seljeflot I, Ueland T. Elevated serum osteoprotegerin levels measured early after acute ST-elevation myocardial infarction predict final infarct size. Heart. 2011;97(6):460-465. doi:10.1136/hrt.2010.206714
  33. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. FREEDOM Trial. N Engl J Med. 2009;361(8):756-765. doi:10.1056/nejmoa0809493
  34. Collin-Osbody P. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res. 2004;95(11):1046-1057. doi:10.1161/01.res.0000149165.99974.12
  35. Panizo S, Cardus A, Encinas M, Parisi E, Valcheva P, López-Ongil S, Coll B, Fernandez E, Valdivielso JM. RANKL increases vascular smooth muscle cell calcification through a RANKL-BMP4-dependent pathway. Circ Res. 2009;104(9):1041-1048. doi:10.1161/circresaha.108.189001
  36. Roysland R, Bonaca MP, Omland T, Sabatine M et al. Osteoprotegerin and cardiovascular mortality in patients with non-ST elevation acute coronary syndromes. Heart. 2012;98(10):786-791. doi:10.1136/heartjnl-2011-301260
  37. Aramburu Bodas O, Conde Martel A, Salamanca Bautista P. Acute heart failure: precipitating factors and prevention. Med Clin (Barc). 2014;142(Suppl.1):9-13. doi:10.1016/s0025-7753(14)70076-4
  38. Berezin AE, Samura TA, Berezina TA, Chuprina SA. The prognostic potential of pro-inflammatory activation markers in patients with coronary heart disease: results of a prospective 1-year study. Ukr Med Chasopis. 2012;2(88):137-141.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.